Search Results - "Merseburger, A.S."

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial by Jayaram, A., Wingate, A., Wetterskog, D., Wheeler, G., Sternberg, C.N., Jones, R., Berruti, A., Lefresne, F., Lahaye, M., Thomas, S., Gormley, M., Meacham, F., Garg, K., Lim, L.P., Merseburger, A.S., Tombal, B., Ricci, D., Attard, G.

“…Plasma tumor DNA fraction is prognostic in metastatic cancers. This could improve risk stratification before commencing a new treatment. We hypothesized that a…”
Get full text

CDK12 expression profile and correlation with tumor associated immune cell infiltrates in prostate cancer by Hupe, M.C., Offermann, A., Schreiber, C., Merseburger, A.S., Perner, S.

Get full text

Does double J stenting during transurethral resection of a bladder tumor increase the risk for metachronous upper urinary tract urothelial cancer development? by Hupe, M.C., Dormayer, L., Ozimek, T., Struck, J.P., Hennig, M.J.P., Klee, M., Von Klot, C.A.J., Kuczyk, M.A., Merseburger, A.S., Kramer, M.W.

Get full text

Role of immunohistochemistry and fluorescence in-situ hybridization (FISH) in the diagnosis of spindle and round cell tumors of the kidney by Abbas, M., Dämmrich, M.E., Braubach, P., Kramer, M.W., Grünwald, V., Merseburger, A.S., Herrmann, T.R.W., Becker, J.U., Kreipe, H.H.

“…Spindle cell/mesenchymal tumors of the kidney are rare. The diagnosis is supported mainly by the application of ancillary techniques such as…”
Get full text

European Association of Urology Guidelines on Laser Technologies by Herrmann, T.R.W, Liatsikos, E.N, Nagele, U, Traxer, O, Merseburger, A.S

“…Abstract Context The European Association of Urology (EAU) Guidelines Office has set up a guideline working panel to analyse the scientific evidence published…”
Get full text

MO-0300 Salvage HDR interventional radiotherapy for prostate cancer after prostatectomy and irradiation by Soror, T., Melcherta, C., Rades, D., Merseburger, A.S., Kovács, G.

Get full text

Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines by Stenzl, A, Cowan, N.C, De Santis, M, Kuczyk, M.A, Merseburger, A.S, Ribal, M.J, Sherif, A, Witjes, J.A

“…Abstract Context New data regarding treatment of muscle-invasive and metastatic bladder cancer (MiM-BC) has emerged and led to an update of the European…”
Get full text

Metastasenchirurgie beim Nierenzellkarzinom by Merseburger, A.S., Kuczyk, M.A., Haverich, A., Krüger, M.

“…Zusammenfassung Hintergrund Etwa 20–30 % der diagnostizierten Nierenzellkarzinome (NCC) weisen bei Erstdiagnose Metastasen auf. Das Risiko für die Entwicklung…”
Get full text

Nebenwirkungen von zielgerichteten Medikamenten bei der Behandlung des metastasierenden Nierenzellkarzinoms by Kirchner, H., Merseburger, A.S.

“…Zusammenfassung Das metastasierende Nierenzellkarzinom (mNZK) lässt sich mit den seit 5 Jahren eingeführten zielgerichteten Medikamenten deutlich besser…”
Get full text

Erratum zu: Nebenwirkungen von zielgerichteten Medikamenten bei der Behandlung des metastasierenden Nierenzellkarzinoms by Kirchner, H., Merseburger, A.S.

Get full text

Splice variant V1 of HYAL4 causes Gemcitabine resistance and predicts Gemcitabine/ Cisplatin failure in metastatic bladder cancer by Hupe, M.C., Hennig, M.J.P.., Lokeshwar, S., Hasanali, S.L., Morera, D.S., Sarcan, S., Terris, M.K., Merseburger, A.S., Lokeshwar, V.B.

Get full text

SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer by Catto, J.W.F., Necchi, A., Powles, T., Guerrero-Ramos, F., Simone, G., Shore, N., Salinas, J.S., Merseburger, A.S., Roumiguie, M., Hiroshi, K., Morris, D.M., Qiang, W., Korkes, F., Hasan, M., Jin, S., Maffeo, J., Hammond, C., Sweiti, H., Somer, R.S., Chang, S.S.

Get full text

A0595 - SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer by Catto, J.W.F., Necchi, A., Powles, T., Guerrero-Ramos, F., Simone, G., Shore, N., Salinas, J.S., Merseburger, A.S., Roumiguie, M., Hiroshi, K., Morris, D.M., Qiang, W., Korkes, F., Hasan, M., Jin, S., Maffeo, J., Hammond, C., Sweiti, H., Somer, R.S., Chang, S.S.

Get full text

2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC) by Necchi, A., Catto, J.W.F., Powles, T.B., Guerrero-Ramos, F., Simone, G., Shore, N.D., Salinas, J., Merseburger, A.S., Roumiguié, M., Kitamura, H., Morris, D., Wei, Q., Korkes, F., Hasan, M., Jin, S., Maffeo, J., Hammond, C., Sweiti, H., Somer, R., Chang, S.S.

Get full text

1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT) by Merseburger, A.S., Agarwal, N., Bjartell, A., Uemura, H., Juárez, Á., Bhaumik, A., Boehm, J., Tran, N., Krochmann, N., Nematian, M., Mundle, S.D., Brookman-May, S.D., Mccarthy, S.A., Chi, K.N.N., Chowdhury, S.

Get full text

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer by Chowdhury, S., Bjartell, A., Agarwal, N., Chung, B.H., Given, R.W., Pereira de Santana Gomes, A.J., Merseburger, A.S., Özgüroğlu, M., Juárez Soto, Á., Uemura, H., Ye, D., Brookman-May, S.D., Londhe, A., Bhaumik, A., Mundle, S.D., Larsen, J.S., McCarthy, S.A., Chi, K.N.

“…The first interim analysis of the phase III, randomized, double-blind, placebo-controlled, multinational TITAN study demonstrated improved overall survival…”
Get full text

Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials by Laukhtina, E., Mori, K., Mostafaei, H., Merseburger, A.S., Nyirady, P., Moschini, M., Quhal, F., Pradere, B., Sari Motlagh, R., Schuettfort, V.M., Enikeev, D., Shariat, S.F.

Get full text

1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial by Ruiz Vico, M., Wetterskog, D., Thakali, S., Orlando, F., Jayaram, A.K., Vainauskas, O., Castellano Gauna, D.E., Martins, K.D., Iwata, K., Gourgioti, G., Serikoff, A., Astrom, L., Matveev, V., Esen, A.A., Feyerabend, S., Senkus-Konefka, E., Gupta, S., Merseburger, A.S., Demichelis, F., Attard, G.

Get full text

Utilization of Facebook, Twitter, YouTube and Instagram in the prostate cancer community by Struck, J.P, Salem, J, Siegel, F, Kramer, M, Tsaur, I, Heidenreich, A, Haferkamp, A, Merseburger, A.S, Borgmann, H

Get full text

Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: A systematic review and network meta-analysis of oncologic and toxicity outcomes by Laukhtina, E., Sari Motlagh, R., Mori, K., Katayama, S., Rajwa, P., Yanagisawa, T., Quhal, F., Mostafaei, H., Grossmann, N.С., König, F., Aydh, A., Pradere, B., Resch, I., Merseburger, A.S., Enikeev, D., Shariat, S.F.

Get full text